CA3026144A1 - Metronomic oral gemcitabine for cancer therapy - Google Patents
Metronomic oral gemcitabine for cancer therapy Download PDFInfo
- Publication number
- CA3026144A1 CA3026144A1 CA3026144A CA3026144A CA3026144A1 CA 3026144 A1 CA3026144 A1 CA 3026144A1 CA 3026144 A CA3026144 A CA 3026144A CA 3026144 A CA3026144 A CA 3026144A CA 3026144 A1 CA3026144 A1 CA 3026144A1
- Authority
- CA
- Canada
- Prior art keywords
- gem
- tumor
- formulation
- mtd
- subject
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Dispersion Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biochemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201662344660P | 2016-06-02 | 2016-06-02 | |
| US62/344,660 | 2016-06-02 | ||
| PCT/CN2017/086942 WO2017206940A1 (en) | 2016-06-02 | 2017-06-02 | Metronomic oral gemcitabine for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3026144A1 true CA3026144A1 (en) | 2017-12-07 |
Family
ID=60479058
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3026144A Pending CA3026144A1 (en) | 2016-06-02 | 2017-06-02 | Metronomic oral gemcitabine for cancer therapy |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US10835548B2 (https=) |
| EP (1) | EP3463298B1 (https=) |
| JP (2) | JP2019517490A (https=) |
| KR (1) | KR102383824B1 (https=) |
| CN (2) | CN114224865A (https=) |
| AU (1) | AU2017273495B2 (https=) |
| CA (1) | CA3026144A1 (https=) |
| ES (1) | ES2898024T3 (https=) |
| TW (1) | TWI814703B (https=) |
| WO (1) | WO2017206940A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2020247912A1 (en) * | 2019-06-06 | 2020-12-10 | Board Of Regents, The University Of Texas System | Lipid nanoparticles containing pharmaceutical and/or nutraceutical agents and methods thereof |
| CN120478381A (zh) * | 2025-07-02 | 2025-08-15 | 华中科技大学同济医学院附属同济医院 | Azd1152和吉西他滨在制备治疗胆管癌药物中的用途 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SI1853250T1 (sl) | 2005-02-18 | 2012-01-31 | Abraxis Bioscience Llc | Kombinacije in reĹľimi dajanja terapevtskih sredstev in kombinirana terapija |
| US8735394B2 (en) | 2005-02-18 | 2014-05-27 | Abraxis Bioscience, Llc | Combinations and modes of administration of therapeutic agents and combination therapy |
| HUE047352T2 (hu) | 2008-09-23 | 2020-04-28 | Nektar Therapeutics | Eljárás ütemezett beadásra kamptotecin elõgyógyszerekkel (például PEG-ironotekánnal) |
| WO2010039039A1 (en) * | 2008-10-03 | 2010-04-08 | Clavis Pharma Asa | Oral formulations of gemcitabine derivatives |
| US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
| CN101926779A (zh) * | 2010-08-19 | 2010-12-29 | 苏州特瑞药业有限公司 | 一种吉西他滨固体脂质纳米粒及其制备方法与用途 |
| KR20140079831A (ko) * | 2011-10-18 | 2014-06-27 | 아지노모토 가부시키가이샤 | 췌장암 및／또는 담도암 치료약 |
| WO2015153820A1 (en) * | 2014-04-02 | 2015-10-08 | Felder Mitchell S | Ctla-4 blockade with metronomic chemotherapy for the treatment of cancer |
-
2017
- 2017-06-02 KR KR1020187038225A patent/KR102383824B1/ko active Active
- 2017-06-02 EP EP17805885.5A patent/EP3463298B1/en active Active
- 2017-06-02 CA CA3026144A patent/CA3026144A1/en active Pending
- 2017-06-02 US US15/612,116 patent/US10835548B2/en active Active
- 2017-06-02 ES ES17805885T patent/ES2898024T3/es active Active
- 2017-06-02 CN CN202210080120.1A patent/CN114224865A/zh active Pending
- 2017-06-02 CN CN201780033938.5A patent/CN109310631A/zh active Pending
- 2017-06-02 WO PCT/CN2017/086942 patent/WO2017206940A1/en not_active Ceased
- 2017-06-02 AU AU2017273495A patent/AU2017273495B2/en active Active
- 2017-06-02 JP JP2018562559A patent/JP2019517490A/ja active Pending
- 2017-06-02 TW TW106118362A patent/TWI814703B/zh active
-
2022
- 2022-04-04 JP JP2022062568A patent/JP2022088622A/ja active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| CN114224865A (zh) | 2022-03-25 |
| AU2017273495B2 (en) | 2023-01-12 |
| JP2019517490A (ja) | 2019-06-24 |
| KR20190015420A (ko) | 2019-02-13 |
| US20170348341A1 (en) | 2017-12-07 |
| WO2017206940A1 (en) | 2017-12-07 |
| AU2017273495A1 (en) | 2018-12-20 |
| EP3463298B1 (en) | 2021-09-01 |
| TW201808309A (zh) | 2018-03-16 |
| TWI814703B (zh) | 2023-09-11 |
| ES2898024T3 (es) | 2022-03-03 |
| EP3463298A4 (en) | 2020-01-01 |
| US10835548B2 (en) | 2020-11-17 |
| CN109310631A (zh) | 2019-02-05 |
| KR102383824B1 (ko) | 2022-04-06 |
| EP3463298A1 (en) | 2019-04-10 |
| JP2022088622A (ja) | 2022-06-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP4035657B1 (en) | Drug composition containing abiraterone acetate, and preparation method therefor and application thereof | |
| CA2626579A1 (en) | Formulation comprising a drug of low water solubility and method of use thereof | |
| CN102770131A (zh) | 卡巴他赛的新颖抗肿瘤用途 | |
| US20160045522A1 (en) | Treatment of Cancer | |
| WO2015187194A1 (en) | Use of paclitaxel particles | |
| KR20210005714A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조합 조성물 및 이의 사용 방법 | |
| KR20210008527A (ko) | 비스플루오로알킬-1,4-벤조디아제피논 화합물을 포함하는 조성물 및 이의 사용 방법 | |
| TWI880897B (zh) | 腫瘤內注射調配物 | |
| JP2025160200A (ja) | クマリン誘導体を含有する、細胞増殖性疾患の治療又は予防用医薬 | |
| JP2022088622A (ja) | がん療法のためのメトロノミック経口ゲムシタビン | |
| JP2022502471A (ja) | 化学療法誘発性の悪心および嘔吐を治療するための方法および製剤 | |
| CN105283178A (zh) | 用于治疗癌症的包含mps-1激酶抑制剂和有丝分裂抑制剂的组合 | |
| PL211114B1 (pl) | Zastosowanie pochodnej epotilonowej w leczeniu choroby nowotworowej | |
| US20060235059A1 (en) | Cancer treatment with epothilones | |
| CN101357134A (zh) | 抗肿瘤效果增强剂和抗肿瘤剂 | |
| TW201716064A (zh) | 供治療癌症之口服投予紫杉醇及Ｐ－ｇｐ抑制劑的治療性組合 | |
| JP2022088622A5 (https=) | ||
| US20060205795A1 (en) | Cancer treatment with epothilones | |
| WO2022170398A1 (en) | Formulations for improved bioavailability of fenretinide | |
| JP2022505222A (ja) | テセタキセルを用いてｃｎｓ腫瘍を治療する方法 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| EEER | Examination request |
Effective date: 20220524 |
|
| D15 | Examination report completed |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D15-D126 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: EXAMINER'S REPORT Effective date: 20240807 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT RECEIVED - RESPONSE TO EXAMINER'S REQUISITION Effective date: 20241119 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20250131 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 8TH ANNIV.) - STANDARD Year of fee payment: 8 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250325 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT DETERMINED COMPLIANT Effective date: 20250325 Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250325 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-P102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: AMENDMENT DETERMINED COMPLIANT Effective date: 20250529 |
|
| P13 | Application amended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P13-X000 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: APPLICATION AMENDED Effective date: 20250529 |
|
| D22 | Grant of ip right intended |
Free format text: ST27 STATUS EVENT CODE: A-2-2-D10-D22-D128 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALLOWANCE REQUIREMENTS DETERMINED COMPLIANT Effective date: 20251205 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-2-2-W10-W00-W100 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: LETTER SENT Effective date: 20260127 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 9TH ANNIV.) - STANDARD Year of fee payment: 9 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260317 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-2-2-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260317 |